

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/568,380	Applicant: Sue Ashwell <i>et al</i>
Filing Date: 02/14/2006	Attorney Docket No.: 101064-1P US
Examiner: Golam M. Shameem	Group Art Unit: 1626
Customer No.: 44992	Confirmation No.: 1041
Title: SUBSTITUTED THIOPHENES AND USES THEREOF	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is being filed in response to the Office Action dated March 5, 2007, (the response date of April 5, 2007, having been extended by four months by a Petition for Extension of Time filed concurrently herewith) in which the Examiner requires Election/Restriction of the claims in the above-identified application.

REMARKS

The Examiner has required restriction to one of the following inventions under 35 U.S.C.121

- I. Claims 1-16 and 26, drawn to a compound of formula (I) classified in class 549 and numerous subclasses.
- II. Claim 17 drawn to compounds of formula (I) classified in class 546 and numerous subclasses.
- III. Claims 20-25 drawn to a method of treatment of a disease classified in class 514 and several subclasses.
- IV. Claim 27 drawn to a process for producing of a compound classified in class 549 and numerous subclasses.

Applicants hereby elect Claims 1-16 and 26, drawn to a compound of formula (I). The applicants provisionally elect the compound of example 4, i.e. 2-[(aminocarbonyl)amino]-5-(4-

methoxyphenyl)-N-[(3S)-piperidin-3-yl]thiophene-3-carboxamide. Elected claims 1-16 and 26 read on the elected species.

The above remarks have been made without prejudice to Applicants right to prosecute any withdrawn subject matter in a timely filed continuation application.

Respectfully submitted,

/Carol A. Loeschorn/

Name: Carol A Loeschorn
Dated: August 6, 2007
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451